Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 8.9% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care (TNDM) is a company specializing in diabetes management solutions, including insulin pumps and related technologies. The company has been focusing on strategic growth initiatives and expanding its international presence.

Why is Tandem Diabetes Care, Inc. going up?

TNDM stock is up 8.9% on Jun 4, 2026 19:41

• Tandem Diabetes Care (TNDM) experienced a bullish movement today, likely driven by positive investor sentiment and growth prospects indicated by recent strategic business model transitions and international expansion efforts.
• The news of key executives, including the CEO and other officers, receiving significant RSU grants under the 2023 Long-Term Incentive Plan could have also contributed to the bullish momentum, signaling confidence in the company's future performance and aligning leadership interests with shareholder value.
• The reaffirmed 2026 guidance and strong solvency profile further reinforced investor confidence in Tandem's long-term prospects, despite near-term profitability challenges.
• Overall, the combination of growth initiatives, executive incentives, and financial stability likely fueled the bullish movement in TNDM stock today.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now

Tandem Diabetes Care (TNDM) is well-positioned for growth due to its successful strategic business model transition and expanding international presence, supported by a strong solvency profile, despite macroeconomic concerns. The company's recent shift to a pay-as-you-go reimbursement model in the U.S. pharmacy channel and its international expansion efforts, particularly with the upcoming Mobi launch, are expected to drive long-term revenue growth. Tandem's strong liquidity and reaffirmed 2026 guidance further bolster its investment appeal, though profitability remains a near-term challenge.

https://www.tradingview.com/news/zacks:82cac7dff094b:0-reasons-to-add-tandem-diabetes-stock-to-your-portfolio-right-now/

Tandem Diabetes Care (TNDM) CEO receives 191,103 RSUs under 2023 incentive plan

Tandem Diabetes Care (TNDM) CEO John F. Sheridan has been granted 191,103 Restricted Stock Units (RSUs) under the company's 2023 Long-Term Incentive Plan. These RSUs represent a contingent right to receive common stock or cash. The vesting schedule begins on May 29, 2027, with one-third vesting initially, followed by eight equal quarterly installments, aiming to align the CEO's interests with shareholder value over the long term.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-3c6439d225dd.html

Tandem Diabetes Care (TNDM) EVP awarded 29,136 RSUs under 2023 incentive plan

Tandem Diabetes Care Inc.'s EVP and Chief Strategy Officer, Elizabeth Anne Gasser, was granted 29,136 restricted stock units (RSUs) under the company's 2023 Long-Term Incentive Plan. This grant is a compensation-related equity award, not an open-market transaction. The RSUs will vest in a staggered schedule, with one-third vesting on May 29, 2027, and the remainder in eight equal quarterly installments thereafter.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-0f077e792eed.html

Tandem Diabetes Care (TNDM) EVP receives 29,136 RSU equity award

Susan Morrison, EVP & Chief Admin. Officer at Tandem Diabetes Care (TNDM), received a grant of 29,136 Restricted Stock Units (RSUs) as part of her equity compensation. These RSUs, which represent a right to receive one share of common stock or cash, will begin vesting on May 29, 2027, with the remaining units vesting in eight equal quarterly installments thereafter. This transaction was reported in a Form 4 filing and is part of the company's 2023 Long-Term Incentive Plan.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-e46f617ae221.html

Tandem Diabetes (TNDM) CFO receives 62,657 restricted stock unit award

Tandem Diabetes Care's CFO, Leigh Vosseller, was granted 62,657 restricted stock units (RSUs) as part of the company's 2023 Long-Term Incentive Plan. This grant is a form of stock-based compensation, not an open-market transaction. The RSUs will begin to vest on May 29, 2027, with one-third vesting then, and the remainder vesting in eight equal quarterly installments.

https://www.stocktitan.net/sec-filings/TNDM/form-4-tandem-diabetes-care-inc-insider-trading-activity-6b5524b7eb84.html

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

XRP ($XRP) Crypto Forecast: Down 5.2% Today

NASDAQ-100 ($NDX) Index Forecast: Down 0.6% Today

Medtronic plc. ($MDT) Stock Forecast: Up 5.0% Today

SL Green Realty Corp ($SLG) Stock Forecast: Up 5.1% Today

SBA Communications Corporation ($SBAC) Stock Forecast: Up 5.0% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.1% Today

Virgin Galactic Holdings Inc ($SPCE) Stock Forecast: Up 12.6% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Up 8.9% Today

Tandem Diabetes Care, Inc. Price History

04.05.2026 - TNDM Stock was up 8.9%

• Tandem Diabetes Care (TNDM) experienced a bullish movement today, likely driven by positive investor sentiment and growth prospects indicated by recent strategic business model transitions and international expansion efforts.
• The news of key executives, including the CEO and other officers, receiving significant RSU grants under the 2023 Long-Term Incentive Plan could have also contributed to the bullish momentum, signaling confidence in the company's future performance and aligning leadership interests with shareholder value.
• The reaffirmed 2026 guidance and strong solvency profile further reinforced investor confidence in Tandem's long-term prospects, despite near-term profitability challenges.
• Overall, the combination of growth initiatives, executive incentives, and financial stability likely fueled the bullish movement in TNDM stock today.

04.05.2026 - TNDM Stock was up 8.0%

• The positive sentiment surrounding Tandem Diabetes Care's (TNDM) leadership team receiving significant Restricted Stock Units (RSUs) under the 2023 Long-Term Incentive Plan could have contributed to the bullish movement in the stock market today. This act of granting equity awards may indicate confidence in the company's future performance.
• Granting RSUs to key executives, including the CEO, EVP, and CFO, helps align their interests with long-term shareholder value. This alignment might enhance investor confidence in TNDM's strategic direction and growth opportunities.
• Despite recent share price fluctuations and concerns over TNDM's valuation, the disclosure of equity awards to top management could potentially reassure investors about the company's dedication to driving sustainable growth and profitability, likely influencing the positive market movement.

01.05.2026 - TNDM Stock was down 6.5%

• TNDM stock saw a decrease today, possibly due to Citigroup maintaining a Neutral rating on the company but revising the price target downward from $22.00 to $17.00. This adjustment, influenced by market changes and competition, may have unsettled investors.
• GuruFocus suggested that TNDM is undervalued by 43.8% based on its GF Value™ and added a "Possible Value Trap" designation, along with insider selling. These factors might have contributed to the negative sentiment towards the stock.
• Despite the undervaluation, investors are advised to be cautious, which could have prompted some to sell their shares, further impacting the decline in TNDM stock today.

29.04.2026 - TNDM Stock was up 18.4%

• Maintaining a Neutral rating but lowering the price target could have initially caused some uncertainty, but the undervaluation by 43.8% may have sparked investor interest.
• The approval of an expanded long-term incentive plan and progress on new insulin pump launches indicate the company's commitment to long-term growth, potentially boosting investor confidence.
• The equity compensation activities of key figures like Chair Emeritus Dick Allen and Director Sandra Beaver, receiving RSUs and aligning their interests with shareholders, could have contributed to a positive outlook for the company.
• Overall, the combination of strategic growth initiatives, undervaluation, and alignment of interests through equity compensation may have driven the strong bullish movement in TNDM's stock today.

13.04.2026 - TNDM Stock was down 5.5%

• Tandem Diabetes Care (TNDM) stock saw a significant decrease of 14.14% in after-hours trading, despite achieving record revenue and surpassing EPS estimates in Q1 2026.
• The initiation of coverage by Benchmark with a 'Hold' rating, showcasing varied analyst views and possible volatility, may have led to investor uncertainty.
• A research report by StockStory assigning an "Underperform" rating due to worries regarding modest sales growth and high valuation in comparison to business quality could have impacted the bearish trend.
• Despite making positive strides operationally and confirming full-year guidance, investor apprehensions about valuation, expense control, and long-term trends might have influenced the stock's decline.

15.04.2026 - TNDM Stock was down 10.5%

• Tandem Diabetes Care (TNDM) posted a narrower loss, surpassed revenue expectations, and notably expanded its gross margin. Interestingly, the stock saw a significant 23.6% decline post-earnings, sparking speculation on potential factors:
• Market sentiment may have soured over doubts about the company's sustainability of growth or concerns regarding future sales performance, despite confirming its annual sales outlook.
• The 'Hold' rating from Benchmark upon initiating coverage, suggesting a balanced valuation and potential volatility, could have contributed to investor wariness, leading to downward stock pressure.
• Despite technical signals indicating a possible trend shift, a recent 26.5% decrease in TNDM's share price across four weeks might have influenced investor sentiment, prompting profit-taking and sell-offs.
• Ultimately, a blend of market sentiment, analyst evaluations, and technical indicators likely converged to shape a pessimistic short-term outlook for Tandem Diabetes Care (TNDM), contrasting with positive financial results and growth potential in the long run.

27.04.2026 - TNDM Stock was down 5.0%

• Shareholders' approval of an expanded long-term incentive plan and recent equity compensation activities involving key individuals at Tandem Diabetes Care could have raised concerns among investors regarding the company's long-term growth outlook and talent retention.
• The company's issuance of stock-based compensation and the granting of restricted stock units (RSUs) to directors may have sparked uncertainties about TNDM's financial stability and strategic path, leading to a lack of confidence in its future performance.
• Despite advancements in new insulin pump releases and optimistic revenue and earnings growth forecasts by 2029, the intensifying competition and possible margin pressures mentioned in recent updates might have contributed to TNDM's bearish market activity.
• The emphasis on aligning management and shareholder objectives for prolonged growth, while crucial, may have also highlighted existing hurdles and uncertainties within the company, further influencing investor sentiment and prompting the downward movement in TNDM's stock price.

02.05.2026 - TNDM Stock was down 5.4%

• An upgrade of Tandem Diabetes Care to "Overweight" with an increased price target to $27 did not prevent the bearish movement, indicating other market factors at play.
• Historical challenges, such as a significant decline in stock price over the past year and low return on equity, likely contributed to the bearish trend.
• The filing of a shelf registration for an ESOP-related offering and changes in director removal rules may have raised concerns among investors.
• Despite the recent surge in stock price and positive sales data, the overall market sentiment towards Tandem Diabetes Care remains cautious, emphasizing the need for a thorough evaluation of the company's long-term prospects.

20.04.2026 - TNDM Stock was up 5.1%

• Tandem Diabetes Care (TNDM) experienced a bullish market movement today, likely driven by positive sentiment and confidence in the company's leadership and growth prospects.
• The routine equity compensation activities reported by TNDM's legal chief, CTO, and EVP may have instilled trust and stability among investors, showcasing commitment and alignment of interests with shareholders.
• The focus on the "Silver Economy" and the healthcare sector's growth opportunities, including TNDM's innovative initiatives, could have further boosted investor optimism and contributed to the stock's upward momentum.
• Despite a price target cut by B of A Securities, the overall positive industry outlook and company-specific developments seem to have outweighed this factor, leading to the bullish movement in TNDM's stock price.

08.04.2026 - TNDM Stock was down 9.7%

• Despite strong Q1 2026 financial results and strategic advancements, Tandem Diabetes Care's stock experienced a bearish movement.
• Concerns about the company's transition to a pay-as-you-go pharmacy model may have led to the market's negative reaction, with analysts predicting a potential near-term revenue decline and impact on earnings per share.
• Investors could be cautious due to short-term challenges from the operational shift, despite the company's positive long-term outlook and innovations in diabetes technology.
• The bearish movement might also result from profit-taking actions following the stock's recent strong performance and analyst upgrades, prompting investors to reassess their Tandem Diabetes Care positions.

11.04.2026 - TNDM Stock was down 6.2%

• Tandem Diabetes Care (TNDM) displayed a reduction in losses during Q4 2025, challenging bearish views and suggesting the potential for improved profit margins going forward.
• Mizuho Securities maintained a Hold rating on TNDM while increasing the target price to $24, reflecting their continuous evaluation of the company's financial outlook.
• Despite receiving FDA clearance for its Control-IQ+ technology for pregnancy use, TNDM's stock price has declined year-to-date, prompting discussions about undervaluation and a potential fair value of $30.76.
• Tandem Diabetes Care announced strong financial results for Q1 2026, including record pump shipments and sales, showcasing its dedication to innovation and expansion.

12.04.2026 - TNDM Stock was up 5.0%

• Tandem Diabetes Care reported impressive Q1 2026 earnings, beating estimates with a revenue of $247.22 million and an EPS of -$0.30, showing a 5.46% year-over-year increase. This positive financial performance likely fueled investor confidence and contributed to the bullish movement in the stock.
• Despite the record sales and positive operational progress, the stock initially dropped by 14.14% in after-hours trading, possibly due to investor concerns. However, the company's reaffirmation of its full-year guidance and growth expectations from new technologies and business models could have reassured investors, leading to the bullish trend.
• Truist Financial maintaining a Buy rating on Tandem Diabetes Care, albeit with a slightly reduced target price, indicates continued optimism in the company's future prospects. This vote of confidence might have further supported the bullish momentum in the stock.
• Tandem Diabetes Care's strategic initiatives, such as expanding internationally, launching new products like Control-IQ+ for pregnant women, and addressing supply chain challenges, demonstrate a proactive approach to growth. These factors, combined with the positive earnings report, likely contributed to the bullish market movement of the stock.